Swiftalyn Numbing Cream

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of minor aches and pains associated with muscles and joints. It is intended for use in adults and children as directed.

Limitations of Use: This drug is not intended for the treatment of severe pain or for prolonged use beyond the recommended duration.

Dosage and Administration

For adults, it is recommended to clean and dry the affected area when practical before application. The product should be applied externally to the affected area up to three times daily.

For children under 12 years of age, it is advised to consult a doctor prior to use.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

For external use only. It is imperative to avoid contact with the eyes or mucous membranes to prevent irritation or adverse reactions. The product should be used strictly as directed to ensure safety and efficacy.

Healthcare professionals should monitor patients for any signs of worsening conditions or lack of improvement within 7 days of use. If symptoms being treated do not subside, or if there is an increase in redness, irritation, swelling, pain, or other adverse symptoms, further evaluation is warranted.

In the event of an allergic reaction to any of the ingredients in this product, immediate medical attention should be sought. Additionally, if the product is ingested, it is crucial to obtain medical help or contact a Poison Control Center at 1-800-222-1222 without delay.

Side Effects

Patients using this product should be aware of several important warnings and potential adverse reactions. This product is intended for external use only, and contact with the eyes or mucous membranes should be avoided. It is crucial that patients use the product only as directed.

In clinical practice, if a patient's condition worsens or does not improve within 7 days of use, or if symptoms being treated do not subside, it is recommended that they discontinue use and consult a healthcare professional. Additionally, if any redness, irritation, swelling, pain, or other symptoms develop or increase, patients should seek medical advice.

There is a risk of allergic reactions to the ingredients in this product. In the event of an allergic reaction, patients should discontinue use immediately and consult a healthcare provider.

If the product is swallowed, it is imperative to seek medical help or contact a Poison Control Center (1-800-222-1222) without delay.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Swiftalyn Numbing Cream (menthol 1%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a healthcare professional prior to use. It is important to assess the appropriateness of treatment and dosage for this age group, as specific recommendations may vary based on individual health needs and conditions.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is currently no information available regarding the use of SWIFTALYN NUMBING CREAM during pregnancy, including safety concerns, dosage modifications, or any special precautions that should be taken. Healthcare professionals should exercise caution when prescribing this medication to pregnant patients, as the lack of data precludes a comprehensive assessment of potential risks to fetal outcomes. Women of childbearing potential should be advised to discuss their pregnancy status and any potential risks with their healthcare provider before using this product.

Lactation

There are no specific warnings or recommendations regarding the use of SWIFTALYN NUMBING CREAM in lactating mothers. Additionally, there is no information available about the potential for excretion of the product in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical help without delay. It is recommended to contact a Poison Control Center at 1-800-222-1222 for expert guidance on managing the situation.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. Healthcare providers should be prepared to assess the patient's condition and implement appropriate management strategies based on the severity of symptoms and the specific substance involved.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion or misuse. It is important to emphasize the necessity of proper storage and handling to ensure the safety of young individuals.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, maintaining a range of 15–30°C (59–86°F). Care should be taken to keep the product away from direct sunlight and heat to ensure its integrity and efficacy. Proper handling and storage conditions are crucial for maintaining the quality of the product throughout its shelf life.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Swiftalyn Numbing Cream, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)